Agenda
Times are displayed in the event's local time (GMT -05:00)
08:58 - 09:09
Conference Opening & Welcome
09:09 - 09:24
Treatment of Newly Diagnosed Myeloma, New Directions
09:24 - 09:37
Relapsed/Refractory Myeloma: New Options and Optimal Sequence
09:37 - 09:57
Bispecific Monoclonal Antibodies and CAR T Cells: When and How?
09:57 - 10:10
10:10 - 10:40
LIVE Debate: Will Role of Autologous Stem Cell Transplant for Myeloma Change in the Coming 5 Years? YES & NO
10:40 - 10:50
Break
10:50 - 11:20
LIVE Debate : Will MRD Become Part of Clinical Decision Making in Myeloma in the Coming 5 Years? YES & NO
11:20 - 11:34
Role of MRD in Acute Leukemias: Today and Tomorrow
11:34 - 11:54
MDS Novel Insights on Biology and Intervention
11:54 - 12:01
12:01 - 12:31
LIVE Debate: Should Allogeneic Transplant be Offered to an MRD Negative AML Patient? YES & NO
12:31 - 12:40
Break
12:40 - 13:10
LIVE Debate: Is There a Role for Maintenance Therapy in AML? YES & NO
13:10 - 13:21
Break
13:21 - 13:25
Message from BMS
13:25 - 14:25
LIVE Satellite Symposium Sponsored by BMS - Reblozyl Branded MDS Indication. It is been provided to assist you in communicating important prescribing information for REBLOZYL® (luspatercept-aamt)
14:25 - 14:44
Newly Diagnosed Diffuse Large B-Cell Lymphoma: New Directions
14:44 - 14:59
Role of Autologous Stem Cell Transplant and CAR T Cell Therapy in Relapsed Lymphoma
14:59 - 15:17
Bispecific Monoclonal Antibodies and CAR T Cells: When and How?
15:17 - 15:26
15:30 - 16:00
LIVE Debate: Is Autologous Stem Cell Transplant still a Standard of Care for Mantle Cell Lymphoma? YES & NO
16:00 - 16:10
Break
16:10 - 16:40
LIVE Debate: Should Every Hodgkin Lymphoma Patient Receive Chemotherapy and an Antibody Drug Conjugate in the First Line? YES & NO
16:40 - 16:57
Novel Treatment Options and Role of MRD in the Management of Chronic Lymphocytic Leukemia
16:57 - 17:11
Chemotherapy-free Treatment Options in Low-risk Lymphoma
17:11 - 17:22
17:22 - 17:52
LIVE Debate: Is There Still a Role for Consolidation Radiation Therapy in Early Stage Hodgkin Lymphoma? YES & NO
17:52 - 18:05
Break
18:05 - 18:35
LIVE Debate: Should Every T-Lymphoma Patient Receive Chemotherapy and an Antibody Drug Conjugate in the First Line? YES & NO
18:35 - 18:47
Break
18:47 - 18:50
Message from Adaptive Biotechnologies
18:50 - 19:30
LIVE Satellite Symposium Sponsored by Adaptive Biotechnologies - MRD Assessment in the Management of Patients with Lymphoid Malignancies
19:30